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S U M M A R Y
Objectives: Invasive aspergillosis (IA) is an important cause of mortality and morbidity in children with
hematological malignancies. Themonitoring of serum galactomannan (GM) antigen is considered useful
in the diagnosis of IA . The aim of this study was to determine the utility of serum GMmonitoring in the
early diagnosis of IA and the role of positive antigenemia in the management of children with acute
lymphoblastic leukemia (ALL).
Methods: The cases of 141 children who were being treated for ALL in the Division of Pediatric
Hematology of the Medical School of Ege University between January 2006 and February 2015 were
reviewed retrospectively. Cases of proven and probable IA were deﬁned according to the European
Organization for the Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) criteria.
Results: The incidence of proven and probable IA was 3.5% (5/141). The incidence of positive GM
antigenemia among 3264 serum samples was 5.5% (n = 179). Of the cases detected, 21.7% were true-
positive, 52.1% were false-positive, and the remaining 26.1% were classiﬁed as ‘undetermined.’ An
increase in the incidence of true-positive tests and induction of antifungal therapy was determined
through multiple consecutive positive tests.
Conclusions: GM may be detected in the serum before the clinical signs of IA appear, but its sensitivity
and speciﬁcity are variable. False-positivity is a signiﬁcant disadvantage, and consecutive positive GM
must be taken into account in the case of clinical and imaging ﬁndings that are relevant to IA.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).1. Introduction
Invasive fungal infections (IFIs), especially those due to
Aspergillus spp, are increasing in children with hematological
malignancies, and despite the introduction of new antifungal
agents, this increase is associated with high morbidity and
mortality rates.1 The early diagnosis and treatment of invasive
aspergillosis (IA) is critical to improving patient outcomes. The
mortality from IA is in the range of 40–90%, and this is affected by
the timing of initiation of therapy.2,3 A mortality rate of 90% has
been reported for patients with pulmonary aspergillosis ﬁrst* Corresponding author. Tel.: +90 2323901113.
E-mail address: dyilmazk@yahoo.com (D.Y. Karapinar).
http://dx.doi.org/10.1016/j.ijid.2016.10.027
1201-9712/ 2016 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).treatedwith antifungal agentsmore than 10 days after the onset of
pneumonia .4
Difﬁculties in the early diagnosis of IA result in delays in the
initiation of antifungal therapy. Due to the non-speciﬁc clinical
symptoms, low sensitivity, long wait for results, difﬁculty in
obtaining positive blood cultures, and lack of appropriate
conditions (uncorrected thrombocytopenia [1_TD$DIFF], coagulopathies, etc.)
for procedures like biopsy for tissue culture or bronchoscopy
(bronchoalveolar lavage (BAL)), the early diagnosis of IA in
pediatric hematological malignancies is very difﬁcult. Computed
tomography (CT) images may show lesions that are compatible
with IA (nodular or cavitary lesions, halo sign), but the incidence of
these ﬁndings is low in pediatric patients. Thus, the use of non-
culturemethods such as the galactomannan (GM) assay, 1–3-beta-
D-glucan test, and fungal DNA via PCR-based assays has become
more important in the early diagnosis of IA.5 [2_TD$DIFF]ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Table 1
Characteristics of the patients with acute lymphoblastic leuke-
mia
Patients (N=141), n (%)
Age
Median
Range
55 months
3–208 months
Sex
Male
Female
80 (56.8%)
61 (43.3)
Type of ALL
Pre-B-cell ALL
T-cell ALL
Biphenotypic
123 (87.2%)
15 (10.6%)
3 (2.1%)
Risk
Standard risk
Medium risk
High risk
56 (39.7%)
38 (26.9%)
47 (33.3)
ALL, acute lymphoblastic leukemia.
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wall. It is released during cell growth and can be measured in
serum using an enzyme immunoassay (EIA). GM testing allows the
early diagnosis of aspergillosis and the prompt initiation of
antifungal therapy,6 which are criteria for the treatment of IFI
deﬁned by the European Organization for Research and Treatment
of Cancer/Mycosis Study Group (EORTC/MSG).7 Many studies on
adult populations have evaluated the utility, sensitivity, and
speciﬁcity of GM for the early diagnosis of IA, but data on serum
GM testing in children are limited. In addition, most pediatric
studies that have been conducted have focused on patients
diagnosed with high-risk hematological/oncological malignancies
or acute myeloid leukemia (AML), or patients undergoing
hematopoietic stem cell transplantation (HSCT).
The aim of this retrospective study was to investigate the effect
of a positive serum Aspergillus GM antigen assay on the
management of IA. It was also sought to determine its utility for
the diagnosis of IA in children with acute lymphoblastic leukemia
(ALL).
2. Methods
Data on pediatric patients with ALL during the period 2006–
2015 were analyzed retrospectively. GM testing was performed
twice a week during the period of neutropenia for all ALL patients.
The demographic and clinical characteristics of the patients were
evaluated for IFI. The total number of GM serum tests performed,
number of positive and negative test results, and number of
consecutive positive tests were analyzed. The effect of positive test
results on the management of patients and how they affected
clinician decision-making, imaging rates, and therapeutic strate-
gies were investigated. Antifungal therapies given for IA despite
negative test results were also recorded. Patients with at least one
positive GM assay were investigated in detail for the presence of
clinical ﬁndings (prolonged or unexplained fever, sinus tenderness,
lower respiratory tract infection, cough, sputum, respiratory
distress, hepatosplenomegaly), laboratory ﬁndings (neutropenia,
microbiological results, direct examination for hyphae or cultures),
and imaging ﬁndings (new pulmonary inﬁltrates while receiving
broad-spectrum antibiotics, consolidation, ‘halo’ sign, ‘air crescent’
sign, cavitation) suggestive of IFI.
The diagnosis of possible, probable, and proven IFI was
determined using the EORTC/MSG criteria.7 Thus, IA was consid-
ered ‘proven’ in the presence of positive microbiology (a positive
microscopy, culture) or histopathology from a sterile site.
‘Probable’ IA was deﬁned by the presence of typical clinical and/
or radiological ﬁndings with mycological criteria. The mycological
criteria include microscopy, culture (sputum or BAL), and positive
GM antigenemia (two or more consecutive positive serum results
of 0.5, or a positive BAL GM result of 0.5). IA was considered
‘possible’ in cases with the appropriate host factors and with
sufﬁcient clinical evidence consistent with IFI but for which there
was no mycological support.
2.1. Positive galactomannan antigenemia
GM test results with an optical density index (ODI) of 0.5 are
considered positive at the study hospital. Thus, episodes of positive
GM antigenemia were deﬁned as at least one ODI of 0.5 in this
study. Consecutive positivity was deﬁned as two or more
consecutive test results of 0.5. Test results were evaluated in
terms of true-positives and false-positives. True-positive anti-
genemia was deﬁned as a positive GM test with the diagnosis of
proven or probable IA. GM antigenemiawas considered to be false-
positive in the absence of the criteria suggestive of proven or
probable IA. These criteria are explained as follows: no speciﬁcradiographic abnormalities on CT, or no speciﬁc clinical symptoms
so CT was not performed. GM antigenemia was considered to be
‘unclear’ if non-speciﬁc abnormalities were determined on CT
during antifungal therapy.
2.2. Impact on management
A positive GM was considered to provide a clinical effect in the
following cases: if a CT scan was performed after the positive test
result and/or if a positive test result led clinicians to start, add, or
change antifungal therapy.
2.3. Statistical analysis
The data analysis was performed using IBM SPSS Statistics
version 20.0 software (IBM Corp., Armonk, NY, USA). Dependence
with each of the variables was analyzed by Chi-square test.
3. Results
3.1. Patient characteristics
A total of 141 patients were included in the study. Sixty-one
were female and 80 were male. The median age was 55 months
(range 3–208 months). One hundred and twenty-three of the
patients (87.2%) had pre-B-cell ALL, 15 (10.6%) had T-cell ALL, and
three (2.1%) had biphenotypic ALL. Fifty-six of the patients (39.7%)
were classiﬁed as standard risk, 38 (26.9%) as medium risk, and 47
(33.3%) as high risk. Furthermore, t(9;22) translocation was
positive in 6.3% of ALL cases. A poor prednisolone response at
day 8 was seen in 43 patients (30.5%) (peripheral blood smear
revealed >1000/mm3 [3_TD$DIFF] lymphoblasts[1_TD$DIFF]). Bone marrow examination
revealed<25% lymphoblasts in 113 (80.1%) and<5% lymphoblasts
in 35 (24.8%) of the patients at day 15. Under 5% lymphoblasts in
bone marrow at day 33 was found in 128 of the patients (90.7%),
and remission was achieved. Relapse occurred in eight patients
(5.6%) (the characteristics of the patients with ALL are summarized
in Tables 1 and 2).
3.2. GM results
A total of 3264 serum samples from the 141 patients were
analyzed. The median number of GM tests performed for each
patient was 55 (range 0–84). One hundred and seventy-nine (5.5%)
serum samples from 76 patients with an ODI of 0.5 were
considered to represent positive GM antigenemia. The number of
negative tests was 3085 (94.5%) from 65 patients.
Table 2
Comparison of the characteristics of patients with positive and negative galactomannan antigenemia
GM-positive (n=76), n (%) GM-negative (n=65), n (%) p-Value
Risk classiﬁcation
High risk
Medium risk
Standard risk
30 (39.4%)
12 (15.7%)
34 (44.7%)
17 (26.1%)
26 (40%)
22 (33.9%)
NS
Initial WBC count
<1.5109/l
>20.0109/l
>100.0109/l
15 (19.7%)
23 (30.2%)
9 (11.8%)
12 (18.4%)
32 (49.2%)
9 (13.9)
NS
Peripheral blood smear at day 8, lymphoblasts
<1.0109/l
>1.0109/l 58 (76.3%)
18 (23.7%)
55 (84.6%)
10 (15.4%)
0.011
Bone marrow examination at day 15, lymphoblasts
<5%
<25%
>25%
15 (19.7%)
59 (77.6%)
17 (22.3%)
20 (30.7%)
54 (83%)
11 (16.9%)
0.008
Bone marrow examination at day 33, lymphoblasts
<5%
>5% 67 (88.1%)
9 (11.9%)
61 (93.8%)
4 (6.2%)
0.007
t(9;22) positive 6 (7.8%) 3 (4.6%) NS
Relapse 6 (7.8%) 2 (3%) NS
HSCT 8 (10.5%) 4 (6.1%) 0.013
GM, galactomannan; NS, non-signiﬁcant; WBC, white blood cell; HSCT, hematopoietic stem cell transplantation.
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The data of 76 patients who had at least one positive GM with
an ODI of 0.5 were analyzed in detail. Positive serum GM results
were observed only once in 22 patients (28.9%), twice in 16 patients
(21.1%), and three times in 15 patients (19.7%). Twenty-three
patients (30.3%) had consecutive positive GM antigenemia; 16
(21.1%) had at least one consecutive positivity, while seven (9.2%)
had two or more consecutive positive results.
Among the 23 patients with at least one consecutive positive
GM antigenemia, 21.7% were true-positive. The true-positive rate
was 12.5% when there was one consecutive positive and 42.9%
when there were two or more consecutive positives. An increase in
the probability of detection of true positivity was found in the case
of multiple consecutive positives (p = 0.001).
The false-positive rate was 52.1%. Six of the patients (26.1%)
were classiﬁed as ‘undetermined’; patients who had non-speciﬁc
radiographic abnormalities on CT scans and/or a diagnosis of IA
could not be excluded because of ongoing antifungal therapy with
anti-mold agents.
3.4. Clinical and radiological ﬁndings
Febrile neutropenia was treated empirically with broad-
spectrum antibiotics (piperacillin–tazobactam or meropenem
with amikacin); in the case of hemodynamic instability, a
glycopeptide was added empirically. If the fever persisted more
than 72–96 h, the patient was evaluated for IFI. A thorax CT was
performed in addition to sinus CT if there was a clinical suspicion
of fungal sinusitis, and an antifungal agent was initiated
empirically.
In the GM-positive group, clinical ﬁndings were not consistent
with fungal pneumonia in 69 patients (90.8%), while seven of the
patients (9.2%) were considered to have clinical signs suggestive of
fungal pneumonia.
With positive GM antigenemia, the clinicians performed
thorax/sinus CT for 32 patients (42.1%), while CT was not
performed for 44 patients (57.9%) because of a positive GM assay
(in these 44 patients, CT had already been performed recently).Thorax CT revealed ﬁndings compatible with IA in 12 (15.8%) of
the 76 patients with positive GM antigenemia. There were no
signiﬁcant ﬁndings consistent with IA on CT scans in 64 patients
(84.2%).
A statistically signiﬁcant relationship between the compliance
of clinical signs and CT ﬁndings in the diagnosis of fungal
pneumoniawas observed (p < 0.010). CT ﬁndings were compatible
with IA in 12 patients, while they were incompatible with IA in
64 patients. Clinical symptoms of seven patients were consistent
with IA, while they were found to be incompatible in 69 cases. In
addition, 95.3% of the patients with normal CT ﬁndings had no
clinical symptoms compatible with IA; in contrast, only 4.7% of
them had speciﬁc clinical symptoms of IA.
There was a statistically signiﬁcant relationship between CT
ﬁndings and true-positive GM antigenemia for IA (p < 0.001). CT
ﬁndingswere found to be consistentwith IA in all ﬁve patientswho
had true-positive GM antigenemia.
The patients with CT ﬁndings of IA were those for whom
clinicians decided to perform CT because of the positive GM
antigenemia. There was a statistically signiﬁcant relationship
between the CT decision due to GM positivity and CT ﬁndings
suggestive of IA (p < 0.001). This study revealed that clinicians
performed CT without waiting for the test results for all febrile
neutropenia episodes with prolonged fever.
3.5. Antifungal therapy
When a positive serum GM test was detected, 35 (46.1%) of the
patients were already on antifungal therapy: 15 (19.7%) were
receiving caspofungin, 11 (14.5%) were receiving liposomal
amphotericin B, six (7.8%) were receiving voriconazole, and three
(3.9%) were receiving combination therapy. The detection of
positive GM antigenemia led physicians to initiate antifungal
therapy in six patients (7.9%), to add a second antifungal agent in
another six patients (7.9%), and to change antifungal therapy in
only one patient (1.3%). No changes were made in the treatment of
63 patients (82.9%) with positive serum GM antigenemia. In
addition, clinicians started antifungal therapy in 56 of 65 patients
despite a negative serum GM test result.
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increase the rate of initiation of antifungal therapy. There was a
statistically signiﬁcant correlation between these two variables
(p = 0.004). The ratio of starting antifungal therapy was 13.6% in
the case of one GM positivity detected, while it increased to 28.6%
with two or more consecutive positive tests.
3.6. Effect on management
A clinical effect was observed in 33 patients (43.4%). Positive
GM antigenemia resulted in a CT scan in 21 of these patients
(27.6%). CT and changes in the treatment were performed for
10 patients (13.2%); only a change in the treatment was made in
one of the patients (1.3%).
4. Discussion
The aim of this retrospective studywas to evaluate the results of
GM testing in children with ALL and the effect of a positive serum
GM antigenemia result on the management of the condition. GM
testing was performed twice a week during the period of
neutropenia. The results showed that the number of serum GM
tests performed per patient was very high, while consecutive
positive results were detected in only a few patients . It was
observed that some patients who did not have a positive test had
more than 50 serum samples analyzed for GM antigenemia
. Despite so many tests being performed, a clinical effect due to
positive GM antigenemiawas found in less than half of the patients
(43.4%). It was found that clinicians performed CT in all patients for
whom there was a clinical suspicion of IA before the test results
were returned, and clinical ﬁndings weremore important than GM
positivity for patient management. Because it takes time to obtain
GM results (average of 2 days for a single result, 5 days for
consecutive results), clinicians tend to perform CT scans for
patients with signiﬁcant clinical signs or administer antifungal
therapy without previous CT. This explains why clinicians did not
perform a CT scan for 57.9% of the patients, and there was no
change in the treatment of 82.9% of the patients resulting from a
positive GM antigenemia.
GM may be detected in the serum before clinical signs of IA
appear, but its sensitivity and speciﬁcity are variable. The
sensitivity of GM testing varies in the range of 30–100%, while
speciﬁcity has been reported to be >75%.8 Serial GM testing is
recommended both for early diagnosis and the follow-up of
patients with IA as a prognostic marker to evaluate the course of
the disease and the response to antifungal treatment.9 Although
the GM assay is frequently used to help clinicians in the early
diagnosis of IA, a disadvantage of GM testing is the likelihood of
false-positive results. Factors that are known to cause false-
positive results are as follows: cross-reactivity of the GM assay
with a number of ﬁlamentous fungi including the species Fusarium,
Penicillium, Cladosporium, Histoplasma, Blastomyces, Paracocci-
dioides, Cryptococcus, Nigrospora, Paecilomyces, Trichothecium,
Lichtheimia ramosa, and Geotrichum; treatment with piperacil-
lin–tazobactam, amoxicillin–clavulanate, or cyclophosphamide;
the presence of GM in some food, drink, enteral nutrition products,
and intravenous solutions (Plasma-Lyte). In patients undergoing
cytotoxic chemotherapy or who have graft-versus-host disease
(GVHD), gastrointestinal translocation of fungal GM from foodmay
explain false-positive GM antigenemia.10 In neonates and infants,
immaturity of the intestinal mucosa may lead to the translocation
of lipoglycans of Biﬁdobacterium, resulting in false-positive GM
antigenemia.11,12 Greater false-positive results are reportedwithin
the ﬁrst 2 to 4 weeks of cytotoxic chemotherapy in hematological
malignancy and HSCT patients.13False-positive GM antigenemia was higher than expected
(52.1%) in this study. This may be due to several factors: (1)
serum GM tests were studied twice a week, but the index values
were not always reported. The laboratory reported results only as
‘positive’ or ‘negative’ (GM with an ODI of 0.5 was reported as
positive). Consecutive positive tests with an ODI of 0.5 were
deemed to represent positive GM antigenemia, while a single
resultwith anODI of0.7 could not be determined and accepted as
positive GM antigenemia. Some of the single positive results may
have been 0.7 and should have been in the true-positive group.
(2) All of the patients were treated with piperacillin–tazobactam
for febrile neutropenia. (3) Foods, drinks, or enteral nutrition
products and gastrointestinal mucosal damage due to cytotoxic
chemotherapy may have contributed to false-positive GM anti-
genemia.
It is important to know the false-positivity rate of the GM assay,
especially in serum samples, because of the difﬁculties with other
diagnostic methods, such as BAL or tissue biopsy. This is also
important to note becauseGM is used as amicrobiological criterion
of probable IA according to the EORTC/MSG consensus group.
Higher false-positivity rates in pediatric cancer patients than in
adult patients have been reported in the literature.14 One
combined adult–pediatric study showed false-positive antigene-
mia in 10.1% of pediatric patients and only 2.5% of adult patients,
while another study found false-positive results in 44% of pediatric
patients and only 0.9% of adult patients.15 Nevertheless, several
pediatric studies have shown that the false-positive rate for GM
testing is lower than estimated. Hayden et al. reported 12.8% false-
positive GM results in 56 pediatric oncology patients from
990 serum samples using an EIA GM index value of 0.5 for
positive GM antigenemia.15 The false-positive rate of GM in
70 patients undergoing allogeneic HSCT or treatment for acute
GVHD after allogeneic HSCTwas reported to be 12.7% by Steinbach
et al., including only one patient with proven or probable IA.13
Lower false-positive rates of GM in pediatric patients were also
reported in patients with AML or allogeneic HSCT, including a few
patients with proven/probable IA.16,17 In a study of pediatric
hematology patients (leukemia, solid tumor, HSCT) comparing
serum and urine samples in terms of GM positivity, the false-
positive rate of serum samples was 5.2%, while that of urine
samples was 20.2%.18 Various clinical and laboratory studies have
shown that the simultaneous use of antifungal agents reduces
serum GM levels.19,20 The impact of mold-active antifungal
prophylaxis and empirical or pre-emptive therapy in patients
who are considered to be at the highest risk of developing IA can
explain the low rates of proven/probable IA and the predominance
of negative GM results. Similar to the present research, a study on
adults showed that among the positive GM results of patients
undergoing allogeneic HSCT, 65.5% were deﬁned as false-positive,
15.5% as true-positive, and 19% as inconclusive.21 High false-
positive results were considered to be mainly related to
gastrointestinal mucosal damage.
Other than the groups of patientsmentioned above (AML, HSCT,
recurrent leukemia), data on patients with low-risk hematological
diseases, which were considered in the present study, are limited.
Although the retrospective nature and lack of data relating to false-
negative patients are potential limitations, this study may provide
guidance on how serum GM should be monitored in pediatric
patients with ALL. False-positivity is a signiﬁcant disadvantage. In
light of the latest data, consecutive positive GM results must be
taken into account when clinical and imaging ﬁndings are relevant
to IA. Further validation of the serum GM assay for the early
diagnosis of IA in both low- and high-risk patients is necessary and
will be better demonstrated in prospective studies on pediatric
patients.
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